JOHN HENRY SCHRANK JR. M.D.
Prescription History 1194777821
Internal Medicine - Infectious Disease in Greenville, SC

NPI Status: Active since May 17, 2006

Contact Information

811 PENDLETON STREET
SUITES 10 & 11
GREENVILLE, SC
ZIP 29601
Phone: (864) 250-0607
Fax: (864) 250-0608

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for JOHN HENRY SCHRANK JR. M.D., an active Infectious Disease specialist practicing in Greenville, SC. Our medical registry currently tracks 11 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 393 documented patient claims. Among these therapy options, the most frequently utilized medication is Biktarvy, which accounts for 184 claims alone.


Ampicillin Sodium

Generic Formulation: Ampicillin SodiumSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 30
SC State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills17.4
Peer Average Days Supply51
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,447.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$174.85

State Avg Cost Per Claim

$187.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.

Therapeutic Applications

Ampicillin is used to treat a wide variety of bacterial infections. It is a penicillin-type antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Biktarvy

Generic Formulation: Bictegrav/Emtricit/Tenofov AlaSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 184
30-Day Fills 186.0
Days Supply 5,580
SC State Average Benchmarks
Peer Average Claims113.0
Peer Average 30-Day Fills114.7
Peer Average Days Supply3,441
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 62.8% higher than the standard regional baseline profile for SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $763,835.59 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,151.28

State Avg Cost Per Claim

$3,894.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination product is used by itself to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of 3 different drugs: bictegravir, emtricitabine, and tenofovir alafenamide. Bictegravir is called an integrase strand transfer inhibitor-INSTI. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor. Emtricitabine and tenofovir alafenamide are often called NRTIs. Bictegravir/emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Cefadroxil

Generic Formulation: CefadroxilSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 23
30-Day Fills 35.0
Days Supply 1,014
SC State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills38.8
Peer Average Days Supply531
Conservative Utilization

This provider writes prescriptions for this formulation 36.1% less frequently than the standard regional baseline metric for practitioners inside SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $379.37 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.49

State Avg Cost Per Claim

$15.81

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections. It belongs to a class of drugs known as cephalosporin antibiotics. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Ceftriaxone

Generic Formulation: Ceftriaxone SodiumSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 39
SC State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills26.0
Peer Average Days Supply129
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 52.0% less volume than the regional standard for practitioners inside SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $829.84 across this reporting matrix range.

Provider Avg Cost Per Claim

$69.15

State Avg Cost Per Claim

$75.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.

Therapeutic Applications

Ceftriaxone is used to treat a wide variety of bacterial infections. This medication belongs to a class of drugs known as cephalosporin antibiotics. It works by stopping the growth of bacteria. This drug is not recommended for use in newborns with high blood bilirubin levels and premature infants due to increased risk of side effects. Ask the doctor or pharmacist for details.

Daptomycin

Generic Formulation: DaptomycinSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 70
SC State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills22.7
Peer Average Days Supply150
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,053.02 across this reporting matrix range.

Provider Avg Cost Per Claim

$277.55

State Avg Cost Per Claim

$1,490.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclic lipopeptide antibiotic that inhibits GRAM-POSITIVE BACTERIA.

Therapeutic Applications

This medication is an antibiotic used to treat serious bacterial infections. It works by stopping the growth of bacteria. This medication is not recommended for use in children younger than 12 months due to possible risk of serious side effects.

Dovato

Generic Formulation: Dolutegravir Sodium/LamivudineSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 22
30-Day Fills 22.0
Days Supply 660
SC State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills40.4
Peer Average Days Supply1,210
Conservative Utilization

This provider writes prescriptions for this formulation 45.0% less frequently than the standard regional baseline metric for practitioners inside SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $63,072.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,866.94

State Avg Cost Per Claim

$2,843.30

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains 2 drugs: dolutegravir and lamivudine. It is used to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Lamivudine belongs to a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs). Dolutegravir belongs to a class of drugs known as integrase inhibitors. This medication is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Odefsey

Generic Formulation: Emtricitab/Rilpiviri/Tenof AlaSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
SC State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills39.1
Peer Average Days Supply1,173
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 68.4% less volume than the regional standard for practitioners inside SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $44,348.88 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,695.74

State Avg Cost Per Claim

$3,538.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains 3 different medications: emtricitabine, rilpivirine, and tenofovir alafenamide. It is used to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Emtricitabine and tenofovir alafenamide belong to a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs). Rilpivirine belongs to a class of drugs known as non-nucleoside reverse transcriptase inhibitors (NNRTIs). Emtricitabine/rilpivirine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Sulfamethoxazole-Trimethoprim

Generic Formulation: Sulfamethoxazole/TrimethoprimSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.1
Days Supply 456
SC State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills27.4
Peer Average Days Supply320
Conservative Utilization

This provider writes prescriptions for this formulation 36.0% less frequently than the standard regional baseline metric for practitioners inside SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $223.37 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.96

State Avg Cost Per Claim

$5.66

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.

Therapeutic Applications

This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type). This medication should not be used by children less than 2 months of age due to the risk of serious side effects. This medication treats only certain types of infections. It will not work for viral infections (such as flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Symtuza

Generic Formulation: Darunavir/Cob/Emtri/Tenof AlafSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 450
SC State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills36.7
Peer Average Days Supply1,099
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 58.3% less volume than the regional standard for practitioners inside SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $73,770.12 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,918.01

State Avg Cost Per Claim

$4,627.10

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product contains 4 different medications: darunavir, cobicistat, emtricitabine, and tenofovir alafenamide. Darunavir is known as a protease inhibitor. Cobicistat helps darunavir work better. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor; both kinds of drugs are often called NRTIs. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Triumeq

Generic Formulation: Abacavir/Dolutegravir/LamivudiSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 60
30-Day Fills 60.0
Days Supply 1,800
SC State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills47.3
Peer Average Days Supply1,417
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 30.4% more claims than the standard regional baseline profile for SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $228,267.39 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,804.46

State Avg Cost Per Claim

$3,626.75

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains 3 drugs: abacavir, dolutegravir, and lamivudine. It is used to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Abacavir and lamivudine belong to a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs). Dolutegravir belongs to a class of drugs known as integrase inhibitors. This medication is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Vancomycin Hcl

Generic Formulation: Vancomycin HclSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 24
30-Day Fills 24.0
Days Supply 110
SC State Average Benchmarks
Peer Average Claims13.0
Peer Average 30-Day Fills13.0
Peer Average Days Supply47
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 84.6% higher than the standard regional baseline profile for SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,697.07 across this reporting matrix range.

Provider Avg Cost Per Claim

$112.38

State Avg Cost Per Claim

$88.37

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.

Therapeutic Applications

Vancomycin is an antibiotic used to treat infections. This form of vancomycin is used to treat a certain intestinal condition (colitis) caused by bacteria. This condition causes diarrhea and stomach/abdominal discomfort or pain. When vancomycin is taken by mouth, it stays in the intestines to stop the growth of certain bacteria that cause these symptoms. This antibiotic treats only bacterial infection in the intestines. It will not work for bacterial infections in any other part of the body or for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like JOHN HENRY SCHRANK JR. M.D. provides transparency into local medical care patterns within Greenville, SC.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Infectious Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.